Is DNA a good stock to buy right now?

Based on our 6-factor quantitative model, Ginkgo Bioworks Holdings, Inc. (DNA) receives a "Avoid" rating with a composite score of 25.6/100. It is ranked #4,315 out of 4,446 stocks. Key factor scores: Quality 16/100, Value 12/100, Momentum 37/100. The timing signal is "Bearish". This is quantitative analysis only — not investment advice.

What is the stock rating for DNA?

Ginkgo Bioworks Holdings, Inc. (DNA) has a "Avoid" rating and 1-star score. The composite score of 25.6 ranks it #4,315 among 4,446 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is DNA in?

Ginkgo Bioworks Holdings, Inc. operates in the Healthcare sector (Pharmaceutical Products industry) with a market cap of $420 million. It is classified as a small-cap stock.

Does DNA pay a dividend?

DNA does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is DNA's P/E ratio?

P/E ratio data is not currently available for DNA, which may indicate the company is not yet profitable.

How profitable is DNA?

DNA's quality factor score is 16/100. Gross margin: 67.0%. ROE: -56.7% vs sector average -43.5%. High margins suggest pricing power and competitive moats.

How is DNA valued compared to peers?

DNA's value factor score is 12/100 (higher = cheaper). Key multiples: . Trading at a premium relative to peers.

What is DNA's debt level?

DNA's debt-to-equity ratio is 120%. Sector average: 32%. Moderate leverage is normal for established companies.

DNA has a beta of 2.00, meaning it amplifies market moves. Stability score: 19/100.

Does DNA have high short interest?

DNA's short interest factor score is 40/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

DNA Stock Analysis: Top Small-Cap Avoid (Score 25.6/100) | Blank Capital Research

Data Series	1D	5D	1M	YTD	1Y	3Y	5Y	10Y
DNA	-6.54%	-5.30%	-1.08%	-22.62%	-5.16%	-	-	-
Industry Proxy XLV	-0.23%	+1.08%	-2.21%	-3.53%	+7.62%	-	-	-
U.S. Market SPY	+0.58%	+3.77%	+1.12%	-0.29%	+23.93%	-	-	-
Alpha vs Market	-7.12%	-9.07%	-2.20%	-22.33%	-29.09%	-	-	-
Alpha vs Sector	-6.31%	-6.38%	+1.13%	-19.09%	-12.78%	-	-	-

Metric	DNA	Benchmark
P/E Ratio	-1.5x	-106%
EV/EBITDA	—	—
Price / Book	0.8x

Stock Entity	Score▼	Quality	Value	Momentum	P/E Ratio	ROE	Gross Margin	Net Margin	Rev Growth	D/E Ratio	Market Cap	Compare
AZN ASTRAZENECA PLC	61	43	77	87	45.2x	88.7%	68.6%	28.3%	-	37.0x	$311.3B	VS
SLGL Sol-Gel Technologies Ltd.	57	41	36	98	-	-146.7%	100.0%	-91.7%	-	0.0x	$271M	VS
VMD VIEMED HEALTHCARE, INC.	53	50	63	60	27.6x	9.4%	57.8%	5.4%	30.8%	39.0x	$370M	VS
INVA Innoviva, Inc.	53	50	72	60	15.9x	9.2%	78.6%	23.9%	7.9%	39.0x	$1.7B	VS
HOLX HOLOGIC INC	53	50	43	58	31.7x	10.2%	51.4%	12.9%	3.6%	48.0x	$16.9B	VS
FONR FONAR CORP	52	48	50	57	11.1x	6.5%	88.3%	10.1%	2.4%	33.0x	$117M	VS
JNJ JOHNSON & JOHNSON	52	50	39	65	21.4x	32.9%	67.8%	29.0%	9.3%	51.0x	$588.0B	VS
UTHR UNITED THERAPEUTICS Corp	51	50	63	66	19.4x	18.0%	88.4%	40.7%	11.8%	11.0x	$25.0B	VS
DGX QUEST DIAGNOSTICS INC	51	50	62	55	21.2x	14.2%	33.2%	9.6%	17.5%	79.0x	$21.7B	VS
PFE PFIZER INC	49	50	59	48	11.1x	16.1%	74.7%	22.1%	25.4%	140.0x	$162.4B	VS
DNA Ginkgo Bioworks Holdings, Inc.	26	16	12	37	-	-56.7%	67.0%	-145.3%	-30.9%	120.0x	$420M

Key Ratio	TTM	2025	2024	2023	2022	2021	2020
Gross Margin %	0.7%	-	-	-	-	-	0.8%
Operating Margin %	-1.5%	-1.9%	-2.5%	-3.4%	-4.6%	-5.8%	-1.8%
EBITDA Margin %	-1.1%	-1.5%	-2.2%	-3.2%	-4.5%	-5.7%	-1.4%
Net Margin %	-1.5%	-1.8%	-2.4%	-3.6%	-4.4%	-5.9%	-1.7%
FCF Margin %	-4.9%	-	-	-	-	-	-252.6%
ROE %	-0.6%	-0.6%	-0.8%	-0.8%	-1.2%	-1.2%	-0.3%
ROA %	-0.3%	-0.3%	-0.4%	-0.5%	-0.8%	-0.9%	-0.2%
ROIC %	-59.6%	-49.0%	-61.8%	-62.2%	-100.5%	-92.2%	-111.5%

Key Ratio

TTM

2025

2024

2023

2022

2021

2020

Gross Margin %

0.7%

0.8%

Operating Margin %

-1.5%

-1.9%

-2.5%

-3.4%

-4.6%

-5.8%

-1.8%

EBITDA Margin %

-1.1%

-1.5%

-2.2%

-3.2%

-4.5%

-5.7%

-1.4%

Net Margin %

-1.5%

-1.8%

-2.4%

-3.6%

-4.4%

-5.9%

-1.7%

FCF Margin %

-4.9%

-252.6%

ROE %

-0.6%

-0.8%

-1.2%

-0.3%

ROA %

-0.3%

-0.4%

-0.5%

-0.8%

-0.9%

-0.2%

ROIC %

-59.6%

-49.0%

-61.8%

-62.2%

-100.5%

-92.2%

-111.5%

Line Item	TTM	2025	2024	2023	2022	2021	2020
	$226M	$170M	$227M	$251M	$478M	$314M	$77M
	—	—	—	—	—	—	$61M
Gross Margin	67.0%	---	---	---	---	---	79.6%
	—	$244M	$424M	$581M	$1.1B	$1.1B	$160M
Depreciation	—	$59M	$63M	$71M	$43M	$29M	$14M
Total Operating Expenses	—	$485M	$787M	$1.1B	$2.7B	$2.1B	—
	-$300M	-$315M	-$560M	-$864M	-$2.2B	-$1.8B	-$137M
EBIT	-$300M	-$315M	-$560M	-$864M	-$2.2B	-$1.8B	-$137M
EBITDA	-$237M	-$256M	-$497M	-$794M	-$2.2B	-$1.8B	-$107M
Operating Margin	-152.5%	-185.3%	-246.5%	-343.8%	-462.4%	-582.6%	-178.8%
EBITDA Margin	-105.1%	-150.6%	-218.8%	-315.7%	-453.5%	-573.4%	-139.6%
	—	—	—	$93K	$106K	$2M	$2M
	—	-$314M	-$548M	-$893M	-$2.1B	-$1.8B	—
Income Tax Expense	—	-$837K	-$479K	-$71K	-$15M	-$1M	$2M
	-$288M	-$313M	-$547M	-$893M	-$2.1B	-$1.8B	-$127M
Net Margin	-145.3%	-183.8%	-240.9%	-355.1%	-440.9%	-585.2%	-165.3%
	$-5.64	$-5.64	$-10.54	$-0.46	$-1.25	$-1.35	$-0.10
Diluted EPS	$-5.64	$-5.64	$-10.54	$-0.46	$-1.25	$-1.39	$-0.10
Weighted Avg Basic	—	55M	52M	1.9B	1.7B	1.4B	—
Weighted Avg Diluted	—	55M	52M	1.9B	1.7B	1.4B	—

Line Item

TTM

2025

2024

2023

2022

2021

2020

$226M

$170M

$227M

$251M

$478M

$314M

$77M

—

$61M

Gross Margin

67.0%

---

79.6%

—

$244M

$424M

$581M

$1.1B

$160M

Depreciation

—

$59M

$63M

$71M

$43M

$29M

$14M

Total Operating Expenses

—

$485M

$787M

$1.1B

$2.7B

$2.1B

—

-$300M

-$315M

-$560M

-$864M

-$2.2B

-$1.8B

-$137M

EBIT

-$300M

-$315M

-$560M

-$864M

-$2.2B

-$1.8B

-$137M

EBITDA

-$237M

-$256M

-$497M

-$794M

-$2.2B

-$1.8B

-$107M

Operating Margin

-152.5%

-185.3%

-246.5%

-343.8%

-462.4%

-582.6%

-178.8%

EBITDA Margin

-105.1%

-150.6%

-218.8%

-315.7%

-453.5%

-573.4%

-139.6%

—

$93K

$106K

$2M

—

-$314M

-$548M

-$893M

-$2.1B

-$1.8B

—

Income Tax Expense

—

-$837K

-$479K

-$71K

-$15M

-$1M

$2M

-$288M

-$313M

-$547M

-$893M

-$2.1B

-$1.8B

-$127M

Net Margin

-145.3%

-183.8%

-240.9%

-355.1%

-440.9%

-585.2%

-165.3%

$-5.64

$-10.54

$-0.46

$-1.25

$-1.35

$-0.10

Diluted EPS

$-5.64

$-10.54

$-0.46

$-1.25

$-1.39

$-0.10

Weighted Avg Basic

—

55M

52M

1.9B

1.7B

1.4B

—

Weighted Avg Diluted

—

55M

52M

1.9B

1.7B

1.4B

—

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis — April 2026 Rating, Price, and Forecast

Last updated: April 2026

Company Overview — What Does Ginkgo Bioworks Holdings, Inc. Do?

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Ginkgo Bioworks Holdings, Inc. (DNA) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jason Kelly and employs approximately 640 people. With a market capitalization of $420M, DNA is one of the notable companies in the Healthcare sector.

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Rating — Avoid (April 2026)

As of April 2026, Ginkgo Bioworks Holdings, Inc. receives a Avoid rating with a composite score of 25.6/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.DNA ranks #4,315 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Ginkgo Bioworks Holdings, Inc. ranks #789 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

DNA Stock Price and 52-Week Range

Ginkgo Bioworks Holdings, Inc. (DNA) currently trades at $6.54. The stock gained $0.11 (1.7%) in the most recent trading session. The 52-week high for DNA is $17.58, which means the stock is currently trading -62.8% from its annual peak. The 52-week low is $5.00, putting the stock 30.8% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is DNA Overvalued or Undervalued? — Valuation Analysis

Ginkgo Bioworks Holdings, Inc. (DNA) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.83x, versus the sector average of 2.75x. The price-to-sales ratio is 1.87x, compared to 1.66x for the average Healthcare stock.

At current multiples, Ginkgo Bioworks Holdings, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Ginkgo Bioworks Holdings, Inc. Profitability — ROE, Margins, and Quality Score

Ginkgo Bioworks Holdings, Inc. (DNA) earns a quality factor score of 16/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -56.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -25.8% versus the sector average of -33.1%.

On a margin basis, Ginkgo Bioworks Holdings, Inc. reports gross margins of 67.0%, compared to 71.5% for the sector. The operating margin is -152.5% (sector: -66.1%). Net profit margin stands at -145.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -30.9% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

DNA Debt, Balance Sheet, and Financial Health

Ginkgo Bioworks Holdings, Inc. has a debt-to-equity ratio of 120.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 4.92x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $111M.

DNA has a beta of 2.00, meaning it is more volatile than the broader market — a $10,000 investment in DNA would be expected to move 100.0% more than the S&P 500 on any given day. The stability factor score for Ginkgo Bioworks Holdings, Inc. is 19/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Ginkgo Bioworks Holdings, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Ginkgo Bioworks Holdings, Inc. reported revenue of $226M and earnings per share (EPS) of $-5.64. Net income for the quarter was $-288M. Gross margin was 67.0%. Operating income came in at $-300M.

In FY 2025, Ginkgo Bioworks Holdings, Inc. reported revenue of $170M and earnings per share (EPS) of $-5.64. Net income for the quarter was $-313M. Revenue grew -25.1% year-over-year compared to FY 2024. Operating income came in at $-315M.

In Q3 2025, Ginkgo Bioworks Holdings, Inc. reported revenue of $39M and earnings per share (EPS) of $-1.45. Net income for the quarter was $-81M. Revenue grew -56.4% year-over-year compared to Q3 2024. Operating income came in at $-90M.

In Q2 2025, Ginkgo Bioworks Holdings, Inc. reported revenue of $50M and earnings per share (EPS) of $-1.10. Net income for the quarter was $-60M. Revenue grew -11.7% year-over-year compared to Q2 2024. Operating income came in at $-66M.

Over the past 8 quarters, Ginkgo Bioworks Holdings, Inc. has demonstrated a growth trajectory, with revenue expanding from $56M to $226M. Investors analyzing DNA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

DNA Dividend Yield and Income Analysis

Ginkgo Bioworks Holdings, Inc. (DNA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

DNA Momentum and Technical Analysis Profile

Ginkgo Bioworks Holdings, Inc. (DNA) has a momentum factor score of 37/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 38/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 40/100 reflects moderate short selling activity.

DNA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Ginkgo Bioworks Holdings, Inc. (DNA) ranks #789 out of 838 stocks based on the Blank Capital composite score. This places DNA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing DNA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DNA vs S&P 500 (SPY) comparison to assess how Ginkgo Bioworks Holdings, Inc. stacks up against the broader market across all factor dimensions.

DNA Next Earnings Date

No upcoming earnings date has been announced for Ginkgo Bioworks Holdings, Inc. (DNA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy DNA? — Investment Thesis Summary

The quantitative profile for Ginkgo Bioworks Holdings, Inc. suggests caution. The quality score of 16/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. Momentum is weak at 37/100, a headwind for near-term performance. High volatility (stability score 19/100) increases portfolio risk.

In summary, Ginkgo Bioworks Holdings, Inc. (DNA) earns a Avoid rating with a composite score of 25.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DNA stock.

Related Resources for DNA Investors

Explore more research and tools: DNA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DNA head-to-head with peers: DNA vs AZN, DNA vs SLGL, DNA vs VMD.

Business quality

Valuation edge

Market alpha

Unlock Investment Thesis

Unlock Performance & Technicals

Unlock Valuation Tools

Institutional peer matrix

Dispersion: efficiency vs. valuation

Lateral intelligence network

Unlock Financial Statements

Unlock Ownership & Management

Intelligence Feed

ProQR Therapeutics Collaborates With Ginkgo Bioworks Over Access To 50+ Instrument Autonomous Lab Nebula

60-year-old cigarette helps solve grisly Bay Area cold-case murder

Surprising DNA analysis reveals where Shroud of Turin may have actually originated

New studies of ancient dogs help scientists understand origin of humanity's closest companion

How The Ginkgo Bioworks (DNA) Story Is Shifting As Analysts Revisit Growth And Risk

Unlock Earnings Transcripts

Institutional Intelligence FAQ

Related Research & Tools

Related Healthcare Stocks

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis — April 2026 Rating, Price, and Forecast

Company Overview — What Does Ginkgo Bioworks Holdings, Inc. Do?

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Rating — Avoid (April 2026)

DNA Stock Price and 52-Week Range

Is DNA Overvalued or Undervalued? — Valuation Analysis

Ginkgo Bioworks Holdings, Inc. Profitability — ROE, Margins, and Quality Score

DNA Debt, Balance Sheet, and Financial Health

Ginkgo Bioworks Holdings, Inc. Revenue and Earnings History — Quarterly Trend

DNA Dividend Yield and Income Analysis

DNA Momentum and Technical Analysis Profile

DNA vs Competitors — Healthcare Sector Ranking and Peer Comparison

DNA Next Earnings Date

Should You Buy DNA? — Investment Thesis Summary

Related Resources for DNA Investors

Comments

Institutional Benchmarks

Related research

Get alerted on rating changes

Intelligence Feed

ProQR Therapeutics Collaborates With Ginkgo Bioworks Over Access To 50+ Instrument Autonomous Lab Nebula

60-year-old cigarette helps solve grisly Bay Area cold-case murder

Surprising DNA analysis reveals where Shroud of Turin may have actually originated

New studies of ancient dogs help scientists understand origin of humanity's closest companion

How The Ginkgo Bioworks (DNA) Story Is Shifting As Analysts Revisit Growth And Risk